X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES IPCA LABS VENUS REMEDIES/
IPCA LABS
 
P/E (TTM) x -4.4 28.1 - View Chart
P/BV x 0.2 3.3 4.9% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 VENUS REMEDIES   IPCA LABS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
IPCA LABS
Mar-18
VENUS REMEDIES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs126695 18.1%   
Low Rs61400 15.3%   
Sales per share (Unadj.) Rs301.8260.2 116.0%  
Earnings per share (Unadj.) Rs-24.919.0 -131.1%  
Cash flow per share (Unadj.) Rs2.533.1 7.7%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs293.3213.0 137.7%  
Shares outstanding (eoy) m12.34126.20 9.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.1 14.7%   
Avg P/E ratio x-3.828.9 -13.0%  
P/CF ratio (eoy) x36.716.6 221.8%  
Price / Book Value ratio x0.32.6 12.4%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m1,15469,120 1.7%   
No. of employees `0000.913.3 7.0%   
Total wages/salary Rs m3937,359 5.3%   
Avg. sales/employee Rs Th4,026.12,477.4 162.5%   
Avg. wages/employee Rs Th425.0555.2 76.5%   
Avg. net profit/employee Rs Th-331.8180.6 -183.7%   
INCOME DATA
Net Sales Rs m3,72432,836 11.3%  
Other income Rs m23418 5.4%   
Total revenues Rs m3,74733,254 11.3%   
Gross profit Rs m3954,505 8.8%  
Depreciation Rs m3381,777 19.0%   
Interest Rs m354240 147.5%   
Profit before tax Rs m-2752,905 -9.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32511 6.2%   
Profit after tax Rs m-3072,394 -12.8%  
Gross profit margin %10.613.7 77.3%  
Effective tax rate %-11.517.6 -65.2%   
Net profit margin %-8.27.3 -113.0%  
BALANCE SHEET DATA
Current assets Rs m2,63819,455 13.6%   
Current liabilities Rs m2,30510,076 22.9%   
Net working cap to sales %8.928.6 31.3%  
Current ratio x1.11.9 59.3%  
Inventory Days Days13598 138.3%  
Debtors Days Days4667 69.2%  
Net fixed assets Rs m4,87120,260 24.0%   
Share capital Rs m123252 48.9%   
"Free" reserves Rs m3,49626,633 13.1%   
Net worth Rs m3,61926,886 13.5%   
Long term debt Rs m1,3742,340 58.7%   
Total assets Rs m7,50941,173 18.2%  
Interest coverage x0.213.1 1.7%   
Debt to equity ratio x0.40.1 436.3%  
Sales to assets ratio x0.50.8 62.2%   
Return on assets %0.66.4 9.9%  
Return on equity %-8.58.9 -95.2%  
Return on capital %1.610.8 14.7%  
Exports to sales %047.6 0.0%   
Imports to sales %13.914.9 93.3%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs m5174,884 10.6%   
Fx inflow Rs m015,642 0.0%   
Fx outflow Rs m5174,884 10.6%   
Net fx Rs m-51710,759 -4.8%   
CASH FLOW
From Operations Rs m5143,411 15.1%  
From Investments Rs m-123-1,354 9.1%  
From Financial Activity Rs m-387-1,304 29.7%  
Net Cashflow Rs m4753 0.6%  

Share Holding

Indian Promoters % 32.9 45.9 71.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.4 1.6%  
FIIs % 0.6 25.3 2.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.4 381.6%  
Shareholders   20,121 36,892 54.5%  
Pledged promoter(s) holding % 36.4 2.1 1,699.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  MERCK LTD  GSK PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - FDC LTD. COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS